Mohammad Reza Zangouey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Reza Zangouey has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Shahriar Dabiri
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Abolfazl Yari
Department of Medical Genetics, Afzalipour Faculty of Medicine Kerman University of Medical Sciences Kerman Iran
1 shared publication - Ali Afgar
Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Arash Samoudi
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Asiyeh Afzali
Department of Medical Laboratory of Sciences, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Mahsa Ziasistani
Department of Pathology, Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, 22 Bahman Blvd., Kerman, Iran
1 shared publication
Latest Publications
- 14 December 2025
- Published by Elsevier in Gene Reports
- Vol. 42
Impact of LMNA gene polymorphism (rs581342) on lung cancer susceptibility: Evidence from a southeast Iranian population
- 14 December 2025
- Published by Elsevier in Gene Reports
- Vol. 42
Impact of LMNA gene polymorphism (rs581342) on lung cancer susceptibility: Evidence from a southeast Iranian population
- 3 June 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (2) , 557-568
Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran
Main Purpose This study aimed to determine any association of KRAS and BRAF mutations in colorectal cancer with clinicopathological features and overall survival (OS) of Southeast Iranian colorectal cancer (CRC) patients. Methods Overall, KRAS and BRAF status were assessed in 100 Iranian CRC subjects. A hundred consecutive stages I–IV CRC patients, who underwent surgical tumor resection from February 2012 to August 2015, were prospectively attained from three centers and were enrolled in the research. Direct sequencing and real-time PCR methods were used to the detection of KRAS and BRAF mutations, respectively. Logistic regression models were used to detect associations of KRAS and BRAF mutations with clinical/clinicopathological features. Kaplan–Meier model was used to estimate overall survival. Results In total, KRAS and BRAF mutations were detected in 29 (29%) and 7 (7%) of 100 CRC patients, respectively. BRAF mutations that all comprised V600E and KRAS mutations were found in codon 12, 13, and 61 (72.4%, 20.7 and 6.9%), respectively. In a multivariate analysis, older age (≥ 60) was significantly associated with higher KRAS mutations rate and high BRAF mutation rate was significantly associated with older age (≥ 60) and poorly differentiated tumors. KRAS and BRAF mutant vs. wild type of KRAS and BRAF, 5-year OS was 62.1% vs. 71.8% (p value > 0.05) and 57.1% vs. 67.7% (p value > 0.05), respectively. Conclusion Mutations were found in both KRAS and BRAF genes in Iranian colorectal cancers patients and were associated with clinical/clinicopathologic features. Our data emphasizes the importance of these molecular features in Iranian CRC patients.
- 3 June 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (2) , 557-568
Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran
Main Purpose This study aimed to determine any association of KRAS and BRAF mutations in colorectal cancer with clinicopathological features and overall survival (OS) of Southeast Iranian colorectal cancer (CRC) patients. Methods Overall, KRAS and BRAF status were assessed in 100 Iranian CRC subjects. A hundred consecutive stages I–IV CRC patients, who underwent surgical tumor resection from February 2012 to August 2015, were prospectively attained from three centers and were enrolled in the research. Direct sequencing and real-time PCR methods were used to the detection of KRAS and BRAF mutations, respectively. Logistic regression models were used to detect associations of KRAS and BRAF mutations with clinical/clinicopathological features. Kaplan–Meier model was used to estimate overall survival. Results In total, KRAS and BRAF mutations were detected in 29 (29%) and 7 (7%) of 100 CRC patients, respectively. BRAF mutations that all comprised V600E and KRAS mutations were found in codon 12, 13, and 61 (72.4%, 20.7 and 6.9%), respectively. In a multivariate analysis, older age (≥ 60) was significantly associated with higher KRAS mutations rate and high BRAF mutation rate was significantly associated with older age (≥ 60) and poorly differentiated tumors. KRAS and BRAF mutant vs. wild type of KRAS and BRAF, 5-year OS was 62.1% vs. 71.8% (p value > 0.05) and 57.1% vs. 67.7% (p value > 0.05), respectively. Conclusion Mutations were found in both KRAS and BRAF genes in Iranian colorectal cancers patients and were associated with clinical/clinicopathologic features. Our data emphasizes the importance of these molecular features in Iranian CRC patients.